Product History - CV247

THE OPINIONS GENERATED ARE BASED UPON INDEPENDENT EXAMINATION AND EVALUATION. THESE DATA SHOULD NOT BE CONSTRUED AS DEMONSTRATING THE SAFETY OR EFFICACY OF CV 247 SINCE THE PRODUCT HAS NOT RECEIVED UK REGULATORY APPROVAL TO DATE.

Product History

CV247 is a combination product comprising of Sodium Salicylate, Copper Gluconate, Manganese Gluconate and Ascorbic Acid (Vitamin C) taken as a solution. The product was conceived and initially developed by Mr John Carter, veterinary surgeon, who also advocated that in combination with the therapy a patient also followed an ñorganic Dietò

Mr Carter established the treatment regime after many years of study and empirical research starting in around 1976. The work began after a number of friends and associates as well as many companion animals had succumbed to the effects of cancer. Mr Carterôs hypothesis was that the increasing rate of cancer affecting the human and animal world could have an association with modern food manufacturing methods and the environment. His theory and treatment was aimed at stimulating the individualôs immune system so as to resist the development or progression of cancer. The effect of this theory was repeatedly tested in his Veterinary practice on a compassionate treatment basis. Mr Carterôs interest and the success with the animals he treated led to word of mouth recommendations to tend to other animals suffering from cancer.

CV247 was seen by pet owners to have a notable rate of success on their respective companion animals, and an anecdotal portfolio of satisfied dog owners was compiled. Credibility in the drug and treatment regime increased further when in 1993 Mr Carter was introduced to UCL Ventures, a division of University College London (UCLV). The anecdotal evidence collected persuaded UCLV that the claim should be investigated independently. UCLV agreed to carry out controlled trials and introduced Professor Peter Beverly who at that time was Head of the Tumour Immunology Unit of the Imperial Cancer Fund at University College London. Professor Beverly agreed to undertake a series of controlled experiments on the effect of the treatment on malignant cancers in mice. After gaining the necessary licence to undertake the experiment, the trials were carried out under a formal contract between John Carter and UCL.